Paradigm4’s Marilyn Matz and Zachary Pitluk discuss the challenges of integrating data from heterogeneous sources and how the company’s plaform and apps combine the cutting edge of computer science and a sensibility geared toward the unique needs of pharma and biopharma to provide end-to-end solutions.
The past few years have seen several flashy demonstrations of how artificial intelligence (AI) algorithms may transform biomedical research, particularly with respect to drug discovery.
The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk
Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
